SCHEMBL21063147

SCHEMBL21063147

O=c1nc[nH]c2c1ncn2[C@@H]1O[C@H](CO)[C@@H](F)[C@H]1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
ALDH1A1 P00352 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
PAX8 Q06710 1/20 0.46
HPGD P15428 1/20 0.44
TP53 P04637 2/20 0.42
GMNN O75496 1/20 0.42
NFKB1 P19838 1/20 0.42
DNMT1 P26358 1/20 0.42
THPO P40225 1/20 0.42
MTOR P42345 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
BLM P54132 1/20 0.42
HBB P68871 1/20 0.42
PMP22 Q01453 1/20 0.42
ADORA3 P0DMS8 5/20 0.41
ADORA2A P29274 3/20 0.41
ADORA1 P30542 3/20 0.41
PDE4D Q08499 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Inosine SCHEMBL15903470 0.90 PAX8 (0.57) LMNAALDH1A1TDP1PAX8HPGD
Inosine SCHEMBL20138538 0.90 PAX8 (0.57) LMNAALDH1A1TDP1PAX8HPGD
Inosine SCHEMBL1682742 0.90 PAX8 (0.57) LMNAALDH1A1TDP1PAX8HPGD
Inosine SCHEMBL7633338 0.90 PAX8 (0.57) LMNAALDH1A1TDP1PAX8HPGD
Inosine SCHEMBL568027 0.90 PAX8 (0.57) LMNAALDH1A1TDP1PAX8HPGD
SCHEMBL22883167 0.82 P2RX3 (0.59) LMNAALDH1A1PAX8HPGDADORA3
Inosine SCHEMBL15348254 0.79 SLC29A1 (0.57) LMNAALDH1A1PAX8PMP22ADORA3
Inosine SCHEMBL14126094 0.79 SLC29A1 (0.57) LMNAALDH1A1PAX8PMP22ADORA3
SCHEMBL28637076 0.76 PAX8 (0.47) LMNAALDH1A1PAX8HPGDTP53
SCHEMBL22577506 0.76 PAX8 (0.47) LMNAALDH1A1PAX8HPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3724205-B1 CYCLIC DINUCLEOTIDES AS STING AGONISTS JANSSEN BIOTECH INC (US) 2022-06-22 EP disclosed
US-20210009630-A1 CYCLIC DINUCLEOTIDES AS STING AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2021-01-14 US disclosed
EP-3724205-A1 CYCLIC DINUCLEOTIDES AS STING AGONISTS Janssen Biotech, Inc. (US) 2020-10-21 EP disclosed
WO-2019118839-A1 CYCLIC DINUCLEOTIDES AS STING AGONISTS JANSSEN BIOTECH, INC. (US) 2019-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210009630-A1 CYCLIC DINUCLEOTIDES AS STING AGONISTS STING1, CGAS, IFNAR1 LMNA 356/4885ALDH1A1 4671/4885TDP1 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.